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A. KmR gene, nucleotide sequence 
ATGATTGAACAAGATGGATTGCACGCAGGTTCTCCGGCCGCTTGGGTGGAGAGGCTATTCGGCTATGACTGGGCACA 
ACAGACAATCGGCTGCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTGTCAAGACCG 
ACCTGTCCGGTGCCCTGAATGAACTCCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGC 
GCAGCTGTGCTCGACGTTGTCACTGAAGCGGGAAGGGACTGGCTGCTATTGGGCGAAGTGCCGGGGCAGGATCTCCT 
GTCATCTCACCTTGCTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGG 
CTACCTGCCCATTCGACCACCAAGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCTTGTCGAT 
CAGGATGATCTGGACGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGGATGCCCGA 
CGGCGAGGATCTCGTCGTGACCCATGGCGATGCCTGCTTGCCGAATATCATGGTGGAAAATGGCCGCTTTTCTGGAT 
TCATCGACTGTGGCCGGCTGGGTGTGGCGGACCGCTATCAGGACATAGCGTTGGCTACCCGTGATATTGCTGAAGAG 
CTTGGCGGCGAATGGGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGATTCGCAGCGCATCGCCTTCTA 
TCGCCTTCTTGACGAGTTCTTCTGA 
Figure 10A 
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B. hrcC gene, nucleotide sequence 
ATGTCGCTCGACATGTCGCCTGTCCAGGGCA_AGCTCGATGGCCGTATTCGTGCTCAGAACCCTGAAGAGTTTCTTGA 
GCGGCTGAGTCAGGAATACCACTTCCAGTGGTTCGTCTATAACGACACGCTGTATGTCAGCCCTTCCAGCGAGCACA 
CCTCGGCGCGCATCGAAGTCTCGCCGGATGCGGTGGACGACCTGCAAACGGCGCTGACCGATGTCGGTCTGCTGGAC 
AAGCGTTTTGGCTGGGGCTCGCTGCCTGACGAAGGCGTGGTTCTGGTTCGTGGTCCGGCCAAATACGTGGAGTTTGT 
GCGCGACTACAGCAAGAAAGTCGAAAAGCCCGACGAGAAGGCCGACAAGCAAGATGTTGTCGTGCTGCCACTCAAAT 
ACGCCAACGCGGCTGATCGGACTATTCGCTACCGTGACCAGCAGTTAGTGGTGGCCGGTGTCGCCAGTATTCTTCAA 
GAGCTGCTGGAAAGCCGTTCGCGTGGCGAAAGCATTGACAGCGTGAACCTGTTGCCGGGGCAGGGCAGCAGTGTTGC 
CAACAGCACAGGTGTCGCGGCCGCCGGCCTGCCTTACAACCTGGGCTCCAATGGTATCGATACGGGAGCACTGCAAC 
AGGGCATTGACCGCGTATTGAACTTCAACAGCAAAAAAACTGCCAAGGGTCATGCCTCAGGCAAGGCAAATATCCGC 
GTAAGCGCTGATGTGCGTAACAACTCCGTATTGATTTACGACCTGCCAGAGCGCAAGGCCATGTACCAGAAACTGGT 
CAAGGAGCTGGACGTTCCGCGCAACCTGATCGAAATCGATGCGGTCATTCTCGACATCGACCGCAATGAACTGGCTG 
AACTGTCCAGTCGCTGGAATTTCAATGCCGGCAGCGTCGGAGGTGGTGCCAACCTGTTTGATGCAGGCACCAGTTCA 
ACGTTGTTCTTGCAGAACGCCAGCAAGTTTTCTGCCGAATT~CATGC~CTTGAAGGCAATGGTTCTGCGTCAGTCAT 
CGGCAACCCGTCGATCCTGACCCTGGAGAATCAGCCTGCAGTGATCGACCTCAGTCGCACCGAATACCTGACGGCCA 
CTTCCGAGCGGGCCGCTGACATTCTGCCCATCACGGCGGGCACCAGCCTTCAAGTGATTCCGCGTTCGCTGGACAAC 
GATGGCAAGCCTCAGGTGCAAATGATCGTGGACATCGAGGATGGCCAGATCGATGTGTCGACGATCAATGACACCCA 
ACCCAGTGTGCGCCGAGGCAATGTCAGCACCCAGGCGGTGATTGCCGAGCACGGCTCGCTGGTCATCGGCGGCTTCC 
ACGGTCTGGAAGCCAATGACAGGATTCACAAGATCCCGCTGTTGGGCGACATTCCCTATATCGGCAAGCTGCTGTTC 
CAGTCCCGCAGTCGCGAACTGAGTCAGCGCGAGCGGCTGTTCATTCTGACCCCTCGACTGATCGGCGATCAGGTCAA 
TCCAGCACGCTATGTACAGAACGGCAACCCCCATGACGTCGATGACCAGATGAAGAAAATCAAGGAACGACGTGACG 
GAGGCGAGCTGCCAACGCGGGGCGACATCCAGAAAGTCTTTACCCAAATGATCGACGGCGCCGCCCCGGAAGGCCTG 
CGCGCTGGCCAGACCCTGCCCTTTGAAACCGATAGTCTGTGTGATCCGGGCGAAGGTCTGACGCTTGATGGGCAGCG 
CTCGCAGTGGTTCGTCAAAAAAGACTGGGGTGTTGCTGTGGTGGTTGCGCGTAACAACACGGACAAGCCGGTACGTA 
TCGACGAAAGCCGATGCGGCGGTCGCTGGGTCATCGGCGTTGCGGCCTGGCCTCATGCATGGCTGCAGCCGGGTGAA 
GAAAGTGAGGTGTACATCGCTGTGCGCCAGCCGCAGATATCTAAAATGGCCAAAGAAAGCAGGCCGTCACTGCTCCG 
GGGAGCGAAACCATGA 
Figure 108 
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C.Dis hrcC gene; contains KmE cassette at site 
ATGTCGCTCGI\Cl\TGTCGCCTGTCCAGGGCAAGCTCGATGGCCGc:'ATTCGTGCTCAGAACCCTGAAGAGTTTCTTGA 
GCGGCTGAGTCAGGAATACCACTTCCl\GTGGTTCGTCTATJ\.ACGACACGCTGTATGTCAGCCC':'TCCAGCGAGCACA 
CCTCGGCGCGCATCGAAGTCTCGCCGGATGCGGTGG1\CGT1CCTGCAJ\J\CGGCGCTGACCGATGTCGGTCTGCTGGAC 
AAGCG'ITTTGGCTGGGGCTCGCTGCCTGACGAAGGCGTGGTTCTGGTTCGTGGTCCGGCCAAA?ACG?GGAGTTTGT 
GCGCGACTACAGCAAGAAAGTCGAA.AAGCCCGACGAGAAGGCCGACl\T\GClLl\GATGTTGTCGTGCTGCCACTCAAAT 
ACGCCMCGCGGCTGATCGGACTATTCGCTACCGTGACCAGCAGTTAGTGGTGGCCGGTGTCGCCAGTATTCTTCAA 
GAGCTGC'l'GGAAAGCCGTTCGCGTGGCGAAAGCATTGACAGCGTGAACCTGTTGCCGGGGCAGGGCAGCAGTGTTGC 
CAACAGCACAGG'l'G'l'CGCGGCCGCCGGCCTGCCTTACAACCTGGGC'::'CCMTGGTl\TCGATACGGGAGCACTGCMC 
AGGGCATTGACCGCGTAT'l'GMCTTCAACAGCAAAAAAACTGCCAAGGGTCZl,TGCCTCJ\GGCAAGGCAAATATCCGC 
GTAAGCGCTGATGTGCG'lMCAACTCCGTATTSATTTACGACCTGCCAGAGCGCl\AGGCCI\TGTACCAGAAACTGGT 
CMGGAGCTGGACGTTCCGCGCMCC'l'GA'l'CGAAATCGATGCGGTCATTCTCGACATCGACCGCJ\ATGAACTGGCTG 
AAC T G TCCAGT C GC T GGAAT TT CAAT GC C GGCAGCG l' CGGAGGT GGTGC CPA CC T GT TT Gl\, TGCAGGC7\CCAGTT CA 
ACGTT GT -:c'C'i'TGCAGAAC GC CAGCAAGTTT T CT GCC GAAT 11GCATGctTGCAGTC GACT CT AGAGGJ\,TC:CCGGGT AC 
CGAGCTCGMT".'CGC?AGCTTCACGCTGCCGCAAGCACTCAGGGCGCMGGGCTGCTl'1PJ,,GGl1J:1.GCGGAJ1,CACGT.AG 
AI\l'tGCCAGTCCGCAGAMCGGTGCTGACCCCGGATGAATGTCAGCTACTGGGC'l'ATCTGGACA.AGGGAAAACGCAAG 
CGCAAAGAGA.AAGCAGGTAGCTTGCAGTGGGCTTACATGGCGATAGCTAGAC'l'GGGCGGTTTTATGGACAGCA}\GCG 
AACCGGAATTGCCAGCTGGGGCGCCCTCTGGTMGGTTGGGAAGCCC'l'GCAAAGTAAACTGGATGGCTTTCTTGC:CG 
CCAAGGATCTGATGGCGCAGGGGATCAAGATCTGATCAAGAGACAGGATGAGGATCGTTTCGCATGATTGAACAAGA 
':'GGATTGC:ACGCAGGTTCTCCGGCCGC"'TGGGTGGAGAGGCTATTCGGCTA'l'GACTGGGCACAACAGACAATCGGCT 
GCTCTGATGCCGCCGTGTTCCGGCTGTCAGCGCAGGGGCGCCCGGTTCTTTTTG':1:CAAGACCGACC".'G':1:CCGGTGCC 
CTGAATGAACTCCAAGACGAGGCAGCGCGGCTATCGTGGCTGGCCACGACGGGCGTTCCTTGCGCAGCTGTGCTCGA 
CGmTCTCACTGAAGCGGGAAGGGACTGGC?GCTATTGGGCGAI1.GTGCCGGGGCAGGATCTCCTG'::.'CATC'l'CACCTTG 
CTCCTGCCGAGAAAGTATCCATCATGGCTGATGCAATGCGGCGGCTGCATACGCTTGATCCGGCTACCTGCCCATTC 
GACCACCl',.AGCGAAACATCGCATCGAGCGAGCACGTACTCGGATGGAAGCCGGTCT'.::'GTCGA':'CAGGAc:'GA'I'C'l'GGA 
CGAAGAGCATCAGGGGCTCGCGCCAGCCGAACTGTTCGCCAGGCTCAAGGCGCGGATGCCCGACGGCGAGGA'_'CTCG 
TCGTGl\CCCATCGCGATCCCTGCTTGCCGAATATCJ\.TGGTGGMAJ\,TGGCCGCTTTTCTGGA"'TCATCGACTGTGGC 
CGGCTGGGTGTGGCGGACCGCTATCAGGACA':'AGCGTTGGCTACCCGTGATATTGCTGMGAGCTTGGCGGCGAA'l'G 
GGCTGACCGCTTCCTCGTGCTTTACGGTATCGCCGCTCCCGAT':'CGCAGCGCATCGCCTTCTATCGCCTTCTTGACG 
.7\GTTC:TTC'""G7\GCGGG7\CTCTGGGGTTCGAAc:'TCGAGCTCGGTACCCGGGGATCC:GTCGACTGC$CATGC~CTTGA 
l-\GGCMTGGTTCTGCGTCAGTCJ\TCGGCAACCCGTCGATCCTGACCCTGGAGM.TCAGCCTGCAGTGATCGACCTCA 
GTCGCACCGAATACCTGACGGCCACTTCCG7\GCGGGCCGCTGACATTCTGCCCATCACGGCGGGCACCAGCCTTCP.A 
G'l GA'l"l' CCGCGTT CGCT GGACAACGAT GGCAAGCC T CAGGT GCl\"J\A T GAT CGT GGACATC GAGG AT GGCCAGAT C GA 
TG'l'G'l'CGACGATCAATGACACCCAJ.J:'-CCAGTGTGCGCCGAGGCi"J,TGTCAGCACCCAGGCGGTGATTGCCGAGCACG 
GCTCGC'l'GG'l'CATCGGCGGCTTCCl1.CGGT2TGGAAGCC:AATGP.CAGGl\TTCACAAGATCCCGCTGTTGGGCGACATT 
CCC'l'A'l'A'l'CGGCMGCTGCTGTTCCAGTCCCSCAGTCGCGAACTGl\GTCAGCGCGAGCGGCTGTTCATTCTGACCCC 
'l'CGAC'l'GA'l'CGGCGATCAGGTCAATCCAGCACGCTATGTACAGAACGGCMCCCCCATGACGTCGATGACCAGATGA 
AGAA.l'1.J',,.'l'CMGGAACGACGTGACGGAGGCGAGCTGCCAACGCGGGGCG7\CI\TCCACAAAGTCTMTACCCA~"4,.ATGATC 
GACGGCGCCGCCCCGGAAGGCC'l'GCGCGCTGGCCAGACCCTGCCCTTTGAAl1C:C:G7\T7\GTCTGTGTCATCCGGGCGA 
AGG'::'CTGACGCTTGATGGGCAGCGCTCGCAGTGGT'l'CG'l'CAAPJV'iAGACTGGGGTGTMGC:TGTGGTGGTTGCGCGTA 
ACAACACGGACAAGCCGGTACGTATCGACGAMGCCGATGCGGCGGTCGCTGGGTCATCGGCGTTGCGGCCTGGCCT 
CATGCATGGCTGCAGCCGGGTGAAGAAAGTGAGGTGTACATCGCTG 
Figure 10C 
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OPTIMIZATION OF CORONATINE 
PRODUCTION IN A GENETICALLY 
IMPROVED STRAIN OF PSEUDOMONAS 
SYRINGAE 
2 
noted the remarkable structural and functional homologies 
between coronatine and methyl jasmonate (MeJA), a plant 
growth regulator derived from the octadecanoid signaling 
pathway, which is elicited by biological stress (Feys et al., 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims the benefit of U.S. Provisional 
Patent Application Ser. No. 60/795,474, filed Apr. 27, 2006, 
and U.S. Provisional Patent Application Ser. No. 60/795,475, 
filedApr. 27, 2006, the complete contents ofboth of which are 
hereby incorporated by reference. 
5 1994; Weiler et al., 1994). Coronatine and MeJA induce 
analogous biological responses in many plant tissues, and 
several researchers have suggested that coronatine functions 
as a molecular mimic of the octadecanoid signaling mol-
ecules produced by higher plants (Feys et al., 1994; Weiler et 
10 al., 1994). However, coronatine does not function solely as a 
molecular mimic of MeJA in some plant species (Palmer and 
Bender, 1995), and the mechanism of action for coronatine 
remains unclear. 
While coronatine may cause undesirable effects in plants, 
SEQUENCE LISTING 
This application includes as the Sequence Listing the com-
plete contents of the accompanying text file "Sequence.txt", 
created Apr. 18, 2007, containing 8,336 bytes, hereby incor-
porated by reference. 
15 it has also been shown to have great practical value, both as an 
abscission agent (see, e.g., U.S. patent Publication No. 
20030013609 to Burns & Bender), and as a compound to 
increase taxane production (see U.S. patent Publication No. 
20030175913 to Steele et al.), both of which are herein incor-
20 porated by reference. 
BACKGROUND OF THE INVENTION 
1. Technical Field 
Overproduction of coronatine by strain Pseudomonas 
syringae DC3000-hrcC has been described (Penaloza-
Vazquez et al., 2000). DC3000-hrcC is a strain that contains a 
transposon insertion in the hrcC gene, which encodes a com-
The present invention generally relates to stable bacterial 
strains that are genetically engineered to overproduce coro-
natine, as well as methods for optimizing the yield of coro-
natine from such strains. In particular, the invention provides 
APVl, a stable, genetically engineered strain of Pseudomo-
nas syringae that overproduces coronatine at temperatures 
that are amenable to commercial production. 
25 ponent of the type III secretion system. While strain DC3000-
hrcC does overproduce coronatine, due to the unstable nature 
of the transposon insertion, this strain has been deemed 
unsuitable for commercial production ofCOR. 
The prior art has thus far failed to provide stable bacterial 
30 strains capable of producing large quantities of coronatine 
under conditions that are suitable for commercial production. 
2. Background 
Polyketides constitute a huge family of structurally diverse 
natural products including those with antibiotic, chemothera-
peutic, and antiparasitic activities. Most of the research on 35 
polyketide synthesis in bacteria has focused on compounds 
synthesized by gram-positive bacterial species including 
Streptomyces and other actinomycetes (Hopwood, 1997; 
Katz, 1997). However, Pseudomonas, a gram-negative bac-
terium, produces a variety of antimicrobial compounds from 40 
the polyketide pathway including coronatine, mupirocin 
(pseudomonic acid), pyoluteorin, and 2,4-diacetylphloroglu-
cinol (Bender et al., 1999). 
With respect to coronatine (COR), the molecule is com-
posed of two building blocks of distinct biosynthetic origin 45 
(Parry et al., 1994). One of these is the ethylcyclopropyl 
amino acid coronamic acid (CMA), which is derived from 
L-isoleucine via the intermediacy ofL-alloisoleucine (Parry 
et al., 1994). The other component is coronafacic acid (CFA), 
which is a polyketide derived from acetate, butyrate, and a 50 
four-carbon unit derived from a-ketoglutarate (Parry et al., 
1994; Parry et al., 1996).A brief overview of the biosynthetic 
route to coronatine is shown in FIG.1. With reference thereto, 
COR consists of the polyketide component CFA coupled via 
amide bond formation to the amino acid component, CMA. 55 
CFA is a polyketide derived from three units of acetate, and 
one unit each of pyruvate and butyrate. CMA is derived from 
isoleucine via alloisoleucine. CFA can also be coupled to 
L-alloisoleucine (aile) and L-isoleucine (ile) to form the 
coronafacoyl analogues, CFA-aile and CFA-ile, respectively. 60 
In plants infected with coronatine-producing bacteria, the 
primary symptom elicited by the presence of coronatine is a 
diffuse chlorosis that can be induced on a wide variety of plant 
species (Bender et al., 1999). Coronatine is also known to 
induce hypertrophy ( cell enlargement), inhibit root elonga- 65 
tion, and stimulate ethylene production in plants (Kenyon et 
al., 1992; Sakai et al., 1979). Several research groups have 
SUMMARY OF THE INVENTION 
The present invention provides novel, stable bacterial 
strains that are genetically engineered to overproduce coro-
natine. The bacterial strains are capable of producing coro-
natine under conditions that make their use in large scale 
commercial preparations of this compound feasible. Unlike 
overproducing strains that are unstable due to a transposon 
insertion, the strains provided herein are stable, genetically 
engineered strains that maintain the overproducing pheno-
type over time. One such exemplary strain is Pseudomonas 
syringae APVl (ATCC deposit submitted 19 Apr. 2007, 
Patent Deposit Designation No. PTA-8340) which was pro-
duced by genetically engineering parent strain P. syringae 
DC3000 by stable insertion of the kanamycin resistance 
(Km') gene into the hrcC gene of the type III secretion sys-
tem. In addition to stably producing higher yields of corona-
tine, the genetically engineered strains of the present inven-
tion do so at temperatures that are more amenable to bacterial 
cell culture than previously known overproducing strains 
(e.g. approximately 26° C. instead of 18° C.). Significantly, 
the strains are also non-pathogenic. In addition, the present 
invention provides cell culture methods for optimizing the 
yield of coronatine from the stable, overproducing strains. 
The invention provides a stable genetically engineered 
bacterial strain that overproduces coronatine. In one embodi-
ment, the stable bacterial strain is a Pseudomonas syringae 
bacterial strain. In another embodiment, the stable genetically 
engineered bacterial strain contains a genetically engineered 
mutation of a type III secretion system gene. In some embodi-
ments, the genetically engineered mutation is an insertion of 
a stable genetic element, examples of which include but are 
not limited to antibiotic resistance cassettes such as the kana-
mycin resistance (Km') cassette. In one embodiment of the 
invention, the type III secretion system gene is hrcC. In yet 
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another embodiment of the invention, the stable genetically 
engineered bacterial strain is non-pathogenic. The invention 
also provides a stable genetically engineered bacterial strain 
that overproduces coronatine, wherein the stable genetically 
engineered bacterial strain is a Pseudomonas syringae bacte-
rial strain, and wherein the stable genetically engineered bac-
terial strain contains a genetically engineered mutation of a 
type III secretion system gene. 
The invention further provides a method of producing 
coronatine. The method includes the steps of 1) culturing a 
stable genetically engineered bacterial strain that overpro-
duces coronatine in a culture medium; and 2) removing coro-
natine produced by said stable genetically engineered bacte-
rial strain in said culture medium. In one embodiment, the 
stable genetically engineered bacterial strain is immobilized 
on a matrix in the culture medium. In one embodiment, the 
stable genetically engineered bacterial strain is a Pseudomo-
nas syringae bacterial strain. In yet another embodiment, the 
stable genetically engineered bacterial strain contains a 
genetically engineered mutation of a type III secretion system 
gene. The genetically engineered mutation may be, for 
example, the insertion of a stable genetic element, of which an 
antibiotic resistance cassette ( e.g. a kanamycin resistance 
(Km') cassette) is one example. In one embodiment, the type 
4 
FIG. 5. Coronatine production by Pseudomonas syringae 
DC3000 (parent strain) and APVl (improved strain). The 
initial inoculum was adjusted to an OD600 nm of0.1 in HSS 
medium (Penaloza-Vazquez et al., 2000), and incubated with 
5 shaking (250 rpm.) at 26° C. Aliquots of the two strains (three 
replicates per sampling) were removed at 0, 3, and 5 days, and 
evaluated for COR production by HPLC. 
FIG. 6A-C. Tomato leaves sprayed with (a) P. syringae 
DC3000 (parent strain), (b) APVl (strain improved for COR 
10 production) and (c) water. Photographs were taken 7 days 
after inoculation. 
FIG. 7. Growth of P. syringae pv. tomato DC3000 (parent 
strain) andAPVl (strain genetically improved for coronatine 
production) on tomato. Leaves were inoculated as described 
15 above and bacterial populations were monitored using estab-
lished techniques (Penaloza-Vazquez et al., 2000). 
FIG. 8. Immobilization of P. syringae in calcium alginate. 
Sodium alginate (3%-5%) is dissolved in distilled water and 
mixed with Pseudomonas cells. The suspension is then dis-
20 pensed dropwise into a solution of 0.1 M calcium chloride. 
On a small scale, this can be accomplished using a syringe 
(Bucke, 1987). 
III secretion system gene is hrcC. In one embodiment, the 25 
stable genetically engineered bacterial strain is non-patho-
genic. In one embodiment of the invention, the step of cul-
turing is carried out at approximately 26° C. 
FIG. 9. Semicontinuous batch fermentation of Pseudomo-
nas strain APVl. COR production is shown for freely-sus-
pended and immobilized cells of APVl. Bacteria were incu-
bated in HSS medium at 25° C., and the medium was replaced 
every 24 h. 
FIG. lOA-C. A, nucleotide sequence encoded by the Kmr 
cassette (GenBankAccession No. Ml 7626; SEQ ID NO: 1); 
B, nucleotide sequence ofthehrcC gene (GenBankAccession 
No. AF232004; SEQ ID NO: 2); C, nucleotide sequence of 
The invention further provides a method of inducing 
abscission in a plant. The method includes the step of apply- 30 
ing to the plant coronatine that has been obtained from the 
stable genetically engineered bacterial strain that overpro-
duces coronatine and that is non-pathogenic. 
the hrcC gene disrupted by the KmR cassette as it occurs in P. 
syringae strain APVl (SEQ ID NO: 3). The boxed nucle-
otides indicate the SphI site; underlined nucleotides indicate 
the sequence of the KmR cassette. 
DETAILED DESCRIPTION OF THE INVENTION 
Before explaining the present invention in detail, it is 
The invention further provides a method of inducing 
increased taxane production in plant cells. The method 35 
includes the step of applying to the plant cells coronatine that 
has been obtained from the stable genetically engineered 
bacterial strain that overproduces coronatine and that is non-
pathogenic. The plant cells may be in a plant, or in a plant cell 
culture. 40 important to understand that the invention is not limited in its 
application to the details of the embodiments and steps 
described herein. The invention is capable of other embodi-
ments and of being practiced or carried out in a variety of 
ways. It is to be understood that the phraseology and termi-
A better understanding of the present invention, its several 
aspects, and its advantages will become apparent to those 
skilled in the art from the following detailed description, 
taken in conjunction with the attached figures, wherein there 
is described the preferred embodiment of the invention, sim-
ply by way of illustration of the best mode contemplated for 
carrying out the invention. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a schematic diagram illustrating the biochemical 
pathways involved in the synthesis of coronatine and 
coronafacoyl compounds. 
45 nology employed herein is for the purpose of description and 
not of limitation. 
The present invention provides stable bacterial strains that 
are genetically engineered to overproduce coronatine, when 
compared to wild-type or parent strains of bacteria that have 
50 not been genetically engineered as described herein. Further, 
the bacterial strains do so under conditions that make their use 
FIG. 2 is a functional and physical map of the coronatine 
biosynthetic gene cluster in Pseudomonas syringae pv. gly- 55 
cinea PG4180. 
in large scale preparation of coronatine feasible. In one 
embodiment of the invention, this is accomplished by geneti-
cally engineering a coronatine producing bacterial strain by 
inserting a stable genetic element into the hrcC gene, which 
encodes a component of the type III secretion system. This 
FIG. 3. Insertion of a KmR resistance cassette into the hrcC 
gene of Pseudomonas syringae DC3000. The insertion leads 
to a mutation in hrcC and the two downstream genes (hrpT 
and hrp V). The result is a nonpathogenic strain of P. syringae 
that overproduces coronatine. 
FIG. 4. Production of COR by P. syringae DC3000 and 
APVl (genetically modified derivative ofDC3000) at 18, 26 
and 30° C. Values represent the means from one experiment 
containing three replicates per strain, and vertical bars indi-
cate the SEM. The experiment was repeated with similar 
results. 
approach builds on existing knowledge ofCOR overproduc-
tion by strainPseudomonas syringae DC3000-hrcC, a strain 
that contains a transposon insertion in hrcC (Penaloza-
60 Vazquez et al., 2000). Unfortunately, due to the unstable 
nature of the transposon insertion in DC3000-hrcC, this strain 
has been deemed unsuitable for commercial production of 
COR. Thus, one aim of the invention described below was to 
create new, stable coronatine-producing strains by inserting a 
65 stable genetic cassette into the hrcC gene. Because the cas-
settes that are utilized do not contain genes for transposition, 
they are genetically stable, and the genetically improved 
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strains of the invention are therefore stable as well. In one 
exemplary embodiment, the stable cassette encodes kanamy-
cin resistance (Km'). Kanamycin is relatively inexpensive 
and has been used as a selectable marker in the construction of 
transgenic plants; consequently, use of this marker is an 
acceptable, economical method for selection of hrcC-mu-
tated strains. Significantly, the COR-overproducing bacterial 
strains of the invention are also non-pathogenic. 
One such exemplary strain is Pseudomonas syringae 
APVl, which was produced by genetically engineering par-
ent strain P. syringae DC3000 by insertion of the kanamycin 
resistance (Kmr) gene into the hrcC gene. Without being 
bound by theory, the disruption ofhrcC leads to an interrup-
tion in the transcription of hrcC, hrpT, and hrpV(Peilaloza-
Vazquez et al., 2000; also see FIG. 3). It is important to note 
that hrp V is a regulatory gene, and it is believed that the 
mutation of hrp V leads to an overproduction of coronatine. 
In addition to producing higher yields of coronatine, the 
genetically engineered strains of the present invention do so 
at temperatures that are more amenable to bacterial cell cul-
ture than previously known overproducing strains ( e.g. 26° C. 
instead of 18° C.; see FIG. 4). The stable overproducing 
strains of the invention are thus suitable for use in the large 
scale commercial preparation of coronatine. In addition, the 
present invention provides methods for optimizing the yield 
of coronatine from overproducing strains, e.g. by immobili-
zation of the stable, overproducing bacteria during culture. 
6 
Coronafacic acid biosynthesis requires cfal, cfa2, and cfa3 
(deposited as #U56980), which encode monofunctional pro-
teins similar to the acyl carrier protein, dehydratase, and 
~-ketoacyl synthase, respectively, of type II polyketide syn-
5 thases. Other genes required for coronafacic biosynthesis 
include cfa4 (#JC5748), cf! (#U09027), and cfa5 (#PC4426); 
the latter two genes exhibit an acyl adenylate/CoA ligase 
signature (Liyanage et al., 1995; Penfold et al., 1996). Two 
adjacent genes (cfa6, cfa7) (#AF098795) in the coronafacic 
10 acid biosynthetic gene cluster encode modular type I 
polyketide synthase (PKS) proteins that are required for 
coronafacic acid biosynthesis (Rangaswamy et al., 1998). 
Two additional genes in the coronafacic acid biosynthetic 
cluster, cfa8 and cfa9 (#AF061506), show relatedness to 
15 crotonyl-CoA reductases and thioesterases, respectively. 
Therefore, the complete coronafacic acid PKS exhibits a 
combination of multifunctional and monofunctional 
polyketide synthase proteins. 
A regulatory region was isolated which controls both 
20 coronafacic and coronamic acid production; the nucleotide 
sequence of this region revealed the presence of three genes, 
corP (#U33327), corS (#U33326), andcorR (#U33326) (FIG. 
2A) (Ullrich et al., 1995). The deduced amino acid sequences 
of corP and corR indicated relatedness to response regulators 
25 that function as members of two-component regulatory sys-
tems, and the translational product of corS showed sequence 
similarity to histidine protein kinases that function as envi-
ronmental sensors (Ullrich et al., 1995). CorS functions as a 
histidine protein kinase and phosphorylates CorR (Ran-Coronatine biosynthesis has been intensively studied in 
Pseudomonas syringae pv. glycinea PG4180 because this 
strain is easy to manipulate genetically, consistently synthe-
sizes large amounts of coronatine in vitro (20-40 mg/L ), and 
infects soybean, a host which is easy to cultivate. The coro-
natine biosynthesis genes in P. syringae pv. glycine a PG4180 
are encoded by a 90-kb plasmid designated p4180A (Bender 35 
et al., 1993 ). A 32.8-kb contiguous region of plasmid p4180A 
30 gaswamy and Bender, 2000). CorR functions as a positive 
activator of coronatine gene expression by binding to the 
promoter regions of the coronafacic and coronamic acid tran-
scripts (Penaloza-Vazquez and Bender, 1998; Wang et al., 
1999). 
The invention is based in part on the development of 
genetically engineered stable bacterial strains that overpro-
duce coronatine. By "overproduce" we mean that the geneti-
cally engineered bacteria produce a higher level (i.e. a greater 
amount or quantity) of coronatine than the parent strain from 
is required for coronatine biosynthesis, and a physical map of 
the coronatine gene cluster was developed using the restric-
tion enzymes BamHI and Sstl (see FIG. 2C). Two regions in 
the coronatine biosynthetic cluster contain structural genes 
for coronamic and coronafacic acid biosynthesis; these 
regions are separated by a 3.4-kb regulatory region (REG, 
FIG. 2B). The nucleotide sequence of the 6.9-kb region con-
taining the coronamic acid biosynthetic gene cluster revealed 
the presence of seven genes designated cmaD, cmaE, cmaA, 
cmaB, cmaC, cmaT, and cmaU, the sequences of which are 
known and accessible under GenBank accession number 
AY391839 (all subsequent references to accession numbers 
refer to GenBank accession numbers, unless otherwise indi-
cated) (Budde et al., 1998; Couch et al., 2004; Ullrich and 
Bender, 1994 ). The deduced amino acid sequence encoded by 
cmaD shows relatedness to acyl carrier proteins and contains 
40 which they are derived or constructed, when cultured under 
the same conditions. The parent strain may be a wild type 
bacterial strain, or a bacterial strain that has already under-
gone strain selection, genetic manipulation, or other proce-
dures in the laboratory. For purposes of the present invention, 
45 the parent strain is considered to be the bacterial strain that 
undergoes genetic manipulation to produce the genetically 
engineered, stable overproducing strain of the invention, and 
the overproducing stains of the invention are "from" or "of' 
these parental stains. In general, the novel overproducing 
50 strains of the invention will produce at least about 5 fold or 
more coronatine than does the parental strain, or preferably at 
least about 10 fold or more coronatine, or more preferably at 
least about 15 to 20 fold, or even more ( e.g. about 25-50, or a phosphopanthetheine attachment site, whereas the amino 
acid sequence encoded by cmaE shows similarity to proteins 
with alpha/beta hydro lase folds. The protein product of cmaA 55 
was shown to activate and load alloisoleucine for use in 
coronamic acid biosynthesis (Couch et al., 2004). CmaB 
chlorinates they position of the L-allo-isoleucine, and CmaC 
catalyzes the formation of the cyclopropyl ring from the 
chlorinated L-allo-isoleucine; the latter is then covalently 
attached to CmaD by CmaA and CmaE (Vaillancourt et al., 
2005). CmaT was shown to have thioester activity (Patel et 
al., 1998) and may be involved in the release of free CMA 
(Couch et al., 2004). The last gene in the CMA region is 
cmaU, the protein product of which is related to amino acid 
efflux proteins and may be required for the export of either 
CMA or coronatine from the cell. 
even 100 fold more) coronatine. 
By "stable" we mean that the genetic manipulation that is 
undertaken to produce the overproducing strains of the 
present application results in a permanent alteration to the 
bacterial genome that is stably transmissible to progeny of the 
genetically engineered bacteria. Further, the phenotypic 
60 expression of the genetic alteration is also displayed by the 
progeny of the genetically engineered bacteria, i.e. the prog-
eny also overproduce coronatine. Those of skill in the art will 
recognize that, as with all living organisms, bacteria are sus-
ceptible to occasional random genetic mutations due to a 
65 variety of factors, and if any such mutations ( e.g. point muta-
tions, insertions, deletions, etc.) occur in the overproducing 
strains of the present invention, the bacterial strains so 
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mutated are still to be considered within the purview of the 
present invention, so long as the bacteria still overproduce 
coronatine. Likewise, further purposeful genetic alterations 
may be introduced into the overproducing strains of the 
invention for other purposes, ( e.g. insertion of a superprom- 5 
oter, insertion of genes encoding a labeling entity or charac-
teristic such as fluorescence, insertion of antibiotic resistance 
genes, etc.). However, all such further genetic alterations of 
the overproducing strains of the invention are also contem-
plated in the present invention, so long as the resulting bac- 10 
terial strain retains the ability to stably overproduce corona-
tine. 
8 
means of preventing transcription and/or translation or the 
gene or proper functioning or usual activity of the gene prod-
uct may also occur to those of skill in the art ( e.g. the use of 
inhibitory RNA), and are within the scope of the present 
invention. 
In one embodiment of the invention, a Kmr cassette is 
inserted into a gene (e.g. hrcC gene) in order to produce the 
bacterial strains of the invention. However, those of skill in 
the art will recognize that other stable genetic elements or 
cassettes may also be used in a similar manner and with 
similar results. For example, cassettes encoding other antibi-
otic resistance genes may be utilized ( e.g. resistance to 
chloramphenicol, streptomycin, spectinomycin, tetracycline, 
gentamicin, etc.,) as well as cassettes encoding reporter genes 
By "bacterial strain" we mean the bacterium or bacteria 
that was originally genetically engineered, and all progeny 
thereof. 
In a preferred embodiment of the invention, the parental 
and genetically engineered overproducing bacterial strains 
are of Pseudomonas syringae origin. Pseudomonas syringae 
15 ( e.g. glucuronidase, luciferase, green fluorescent protein, and 
the like). 
is the only bacterium currently known to produce coronatine. 
However, other bacteria are known to produce coronatine 
analogs (e.g. Xanthomonas campestris pv phormiicola; and 
some other bacteria are known to have some of the coronatine 
genes (e.g. Erwinia carotovora). These and any other strains 
that, for example, could be genetically engineered to contain 
the genes for synthesis of coronatine, may also be used in the 
practice of the present invention. 
In a preferred embodiment of the invention, overproduc-
tion of coronatine results from the inactivation of a gene of the 
type III secretion pathway. By "inactivation" we mean that as 
a result of the genetic engineering, the gene product can no 
longer fulfill its usual function in the pathway. The gene 
product may not be transcribed, or be transcribed but not be 
translated, or a defective gene product that is not capable of 
carrying out the usual function of the normal gene product 
may be produced instead. Alternatively, the amount of effec-
tive gene product that is produced may be very low, so much 
so that the pathway as a whole does not function properly. In 
one embodiment of the invention, this is realized by insertion 
In some embodiments, the genetically engineered strains 
of the present invention produce coronatine at temperatures 
that are more amenable to bacterial cell culture than previ-
20 ously known overproducing strains. In one embodiment of 
the invention, the overproducing strains produce COR at tem-
peratures that are greater than about 20° C., and preferably at 
temperatures that are greater than about 25° C. ( e.g. about 26° 
C. or higher). In one embodiment, COR is produced at tem-
25 peratures ranging from about 20° C. to about 30° C. This 
confers a distinct advantage since this temperature range is 
much easier to maintain in a bacterial cell culture setting ( e.g. 
for larger scale fermentations) than is the previously required 
temperature (18° C.). For the purposes of the present inven-
30 tion, the temperature of cultivation of the overproducing 
strains may be the optimal temperature for COR production. 
However, this is not an absolute requirement. The tempera-
ture at which the overproducing bacteria are cultivated need 
not be the absolute optimum, but rather a temperature at 
35 which sufficient COR can be produced to outweigh the prac-
tical constraints of maintaining a lower or higher temperature, 
i.e. the actual optimal yield may be sacrificed in order to 
maintain an environment that is readily achieved and main-
tained. of a genetic element into the hrcC gene of the type III secre-
tion pathway. Without being bound by theory, such an inser- 40 
tion appears to block accurate transcription and/or translation 
In a preferred embodiment of the invention, the CO R over-
producing bacterial strain is APVl, which is derived from P. 
syringae DC3000. In APVl, a kanamycin resistance (Kmr) 
cassette has been inserted into the hrcC gene of the gene 
cluster that encodes the type III secretion system. The amino 
acid sequence of the KmR cassette is provided in FIG. lOA. 
The nucleotide sequence of the hrcC gene is provided in FIG. 
of the gene product of this gene and downstream genes hrpT 
and hrp V, thus disarming the type III secretion pathway. How-
ever, those of skill in the art will recognize that transcription 
and/or translation of other genes in other pathways may also 45 
be carried out to generate overproducing COR bacteria. 
Examples include but are not limited to, for example, gacA 
and gacS. Further, other genes of the type III secretion path-
way may be targeted for mutation/interruption of transcrip-
tion or translation (or translation of a non-functioning gene 50 
product), e.g. (hrpT, hrpV and/or hrpS). In addition, one or 
more of such genetically engineered mutations may be car-
ried out to produce the COR-overproducing bacteria of the 
invention, so long as the resulting bacteria are viable, over-
produce COR, and the genetic change is stable. However, in a 55 
preferred embodiment, the gene is hrcC. This is due, in part 
lOB (see GenBank Accession No. AF232004). The KmR 
cassette was inserted into the SphI site in hrcC (see FIG. lC). 
Those of skill in the art will recognize that many nucleotide 
sequences can encode such an amino acid sequence ( e.g. due 
to the redundancy of the DNA encoding mechanism) and all 
such possible nucleotide sequences (DNA, RNA, etc.) are 
contemplated for use in the present invention. Further, many 
plasmids or other constructs useful for genetic engineering 
may be utilized to make the bacterial strains of the invention. 
An exemplary sequence is that within the operon presented in 
GenBank Accession No. AF232004. In APVl, the cassette 
was inserted in the middle of the gene at the SphI restriction 
site; however, those of skill in the art will recognize that the 
to, for example, the small ( and therefore inconvenient) size of 
e.g. hrp V, and the advantage of rendering the bacterium non-
pathogenic by mutation ofhrcC, which encodes a structural 
portion of the type III secretion system. 
Further, other means of preventing the transcription and/or 
translation of the hrcC ( or another) gene may also be used and 
would result in increased production of coronatine, e.g. dele-
tion and or replacement ofall or portions of the gene, insertion 
60 insertion may be at any location within the gene, and in either 
orientation, so long as the insertion disrupts the normal func-
tioning of or disables the gene product, and preferably, of 
downstream gene products as well. 
of a stop codon into the gene, introduction of mutations into 65 
the gene, gene silencing, etc. All such means are intended to 
be encompassed by the present invention. In addition, other 
The COR-overproducing bacterial strains of the present 
invention are non-pathogenic. As such, they may safely be 
used for direct application to plants for any of a variety of 
reasons, including but not limited to: to induce abscission or 
US 7,579,164 B2 
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fruit loosening to facilitate mechanical harvesting of fruit, 
thereby bypassing the expense of hiring labor for manual 
harvesting by hand; and to induce higher taxane production 
by or in plants to which they are applied. In the latter example, 
it is important to mention that coronatine stimulates the pro- 5 
duction of diterpene taxanes in cell cultures of Taxus spp. And 
this has resulted in a patent application for the use of CO Rand 
related compounds as elicitors oftaxol production (see U.S. 
patent Publication No. 20030175913 to Steele et al., which is 
herein incorporated by reference). The present invention thus 10 
also provides methods for inducing abscission in plants and 
methods for inducing increased taxane production in plants, 
by application to the plant of a non-pathogenic COR-over-
producing bacterial strain of the invention. Alternatively, 
COR overproduced by the methods of the invention may be 15 
applied directly to plants to achieve similar results. 
The present invention also provides methods of making or 
producing coronatine using the overproducing strains of the 
invention. In general, the bacterial strains are cultivated with 
a suitable media (e.g. HSS, HSC, and the like) according to 20 
methods that are well established in the art ( e.g. under sterile 
conditions, with suitable aeration, etc). The coronatine is then 
removed from the culture media by known methods, e.g. 
organic extraction with ethyl acetate, and may then be further 
purified, concentrated, etc. 25 
It has been discovered that immobilization of the COR-
overproducing bacterial cells of the invention on a matrix 
results in further higher yields of COR. Therefore, in a pre-
ferred embodiment of the invention, the overproducing bac-
teria are immobilized on a matrix. Immobilization appears to 30 
protect the cells and to protect cell viability. Those of skill in 
the art will recognize that several techniques and matrices for 
immobilizing bacterial cell cultures are available, and all such 
techniques and matrices are intended to be encompassed by 
the present invention. However, in preferred embodiments, 35 
the immobilization matrix is calcium alginate or Cytoline™ 
2. Examples of other suitable matrices include but are not 
limited to porous glass beads and solid PVA particles, wood 
chips, diatomaceous earth beads, carrageenan, chitosan and 
polysaccharide gels. 
REFERENCES FOR BACKGROUND OF THE 
INVENTION 
40 
Bender, C. L., F. Alarcon-Chaidez, and D. C. Gross. 1999. 45 
Pseudomonas syringae phytotoxins: mode of action, regu-
lation and biosynthesis by peptide and polyketide syn-
thetases. Microbial. Mo!. Biol. Rev. 63:266-292. 
10 
tion di domain enzyme involved in the biosynthesis of coro-
natine. J. Bacterial. 2004 January; 186(1):35-42.; 
Feys, B., Penfold, C. and Turner, J. (1994) Arabidopsis 
mutants selected for resistance to the phytotoxin corona-
tine are male sterile, insensitive to methyl jasmonate, and 
resistant to a bacterial phytotoxin. Plant Cell 6: 7 51-7 59. 
Hopwood, D. A. 1997. Genetic contributions to understand-
ing polyketide synthases. Chem. Rev. 97:2465-2497. 
Ichihara, A., Shiraishi, K., Sato, H., Sakamura, S., Nish-
iyama, K., Sakai, R., Furusaki, A., and Matsumoto, T. 
(1977) The structure of coronatine. J. Am. Chem. Soc. 99: 
636-637. 
Katz, L. 1997. Manipulation of modular polyketide syn-
thetases. Chem. Rev. 97:2557-2575. 
Kenyon, J. S., and J. G. Turner. 1992. The stimulation of 
ethylene synthesis in Nicotiana tabacum leaves by the 
phytotoxin coronatine. Plant Physiol. 100:219-224. 
Liyanage, H., C. Penfold, J. Turner, and C. L. Bender. 1995. 
Sequence, expression and transcriptional analysis of the 
coronafacate ligase-encoding gene required for coronatine 
biosynthesis by Pseudomonas syringae. Gene 153:17-23. 
Palmer, D. A., and Bender, C. L. (1995) Ultrastructure of 
tomato leaf tissue treated with the Pseudomonad phyto-
toxin coronatine and comparison with methyl jasmonate. 
Mo!. Plant-Microbe Interact. 8: 683-692. 
Parry, R. J., S. Jiralerspong, S. Mhaskar, L. Alemany, and R. 
Willcott. 1996. Investigations of coronatine biosynthesis. 
Elucidation of the mode of incorporation of pyruvate into 
coronafacic acid. J. Am. Chem. Soc. 118:703-704. 
Parry, R. J., S. V. Mhaskar, M.-T. Lin, A. E. Walker, and R. 
Mafoti. 1994. Investigations of the biosynthesis of the phy-
totoxin coronatine. Can. J. Chem. 72:86-99. 
Patel, J., J.C. Hoyt, and R. J. Parry. 1998. Investigations of 
coronatine biosynthesis. Overexpression and assay of 
CmaT, a thioesterase involved in coronamic acid biosyn-
thesis. Tetrahedron 54:15927-1593. 
Penaloza-Vazquez, A., and C. L. Bender. 1998. Characteriza-
tion of C or R, a transcriptional activator which is required 
for biosynthesis of the phytotoxin coronatine. J. Bacterial. 
180: 6252-6259. 
Penaloza-Vazquez, A., Preston, G. M., Collmer, A., and 
Bender, C. L. (2000) Regulatory interactions between the 
Hrp type III protein secretion system and coronatine bio-
synthesis in Pseudomonas syringae pv. tomato DC3000. 
Microbiology 146: 2447-2456. 
Penfold, C. N., C. L. Bender, and J. G. Turner. 1996. Char-
acterisation of genes involved in biosynthesis of 
coronafacic acid, the polyketide component of the phyto-
Bender, C. L., H. Liyanage, D. Palmer, M. Ullrich, S. Young, 
and R. Mitchell. 1993. Characterization of the genes con-
trolling biosynthesis of the polyketide phytotoxin corona-
tine including conjugation between coronafacic and coro-
namic acid. Gene 133:31-38. 
50 toxin coronatine. Gene 183:7-173. 
Rangaswamy, V., and C. L. Bender. 2000. Phosphorylation of 
C or S and C or R, regulatory proteins that modulate pro-
duction of the phytotoxin coronatine in Pseudomonas 
syringae. FEMS Microbial. Lett. 193:13-18. 
Bucke, C. 1987. Cell immobilization in calcium alginate. In 
Immobilization Techniques for cells/organelles. Meth. 
Enzymol. 135:175-189. 
55 Rangaswamy, V., S. Jiralerspong, R. Parry and C. L. Bender. 
1998. Biosynthesis of the Pseudomonas polyketide 
coronafacic acid requires monofunctional and multifunc-
tional polyketide synthase proteins. Proc. Natl. Acad. Sci. Budde, I. P., B. H. Rohde, C. L. Bender, and M. S. Ullrich. 
1998. Growth phase and temperature influence promoter 
activity, transcript abundance and protein stability during 60 
biosynthesis of the Pseudomonas syringae phytotoxin 
coronatine. J. Bacterial. 180: 1360-1367; 
Bums, J. K., Pozo, L. V., Arias, C. R., Hockema, B., Ran-
gaswamy, V., and Bender, C. L. 2003. Coronatine and 
abscission in citrus. J. Amer. Soc. Hort. Sci. 128: 309-315. 65 
Couch, R.; O'Connor, S. E.; Seidle, H.; Walsh, C. T., and 
Parry, R. Characterization of CmaA, an a deny lation-thiola-
USA 95:15469-15474. 
Sakai, R., K. Nishiyama, A. Ichihara, K. Shiraishi, and S. 
Sakamura. 1979. The relation between bacterial toxic 
action and plant growth regulation, p. 165-179. In J.M. 
Daly and I. Uritani (ed.), Recognition and specificity in 
plant host-parasite interactions. University Park Press, 
Baltimore. 
Ullrich, M., and C. L. Bender. 1994. The biosynthetic gene 
cluster for coronamic acid, an ethylcyclopropyl amino 
US 7,579,164 B2 
11 
acid, contains genes homologous to amino acid-activating 
enzymes and thioesterases. J. Bacterial. 176:7574-7586. 
Ullrich, M., Penaloza-Vazquez, A., Bailey, A. M., and 
Bender, C. L. (1995) A modified two-component regula-
tory system is involved in temperature-dependent biosyn-
thesis of the Pseudomonas syringae phytotoxin corona-
tine. J. Bacterial. 177: 6160-6169. 
Vaillancourt, F. H.; Yeh, E.; Vosburg, D. A.; O'Connor, S. E., 
and Walsh, C. T. Cryptic chlorination by a non-haem iron 
enzyme during cyclopropyl amino acid biosynthesis. 
Nature. 2005 Aug. 25; 436(7054): 1191-1194. 
Wang, L., C. L. Bender, and M. S. Ullrich. 1999. The tran-
scriptional activator C or R is involved in biosynthesis of 
the phytotoxin coronatine and binds to the cmaABT pro-
moter region in a temperature-dependent manner. Mo!. 
Gen. Genet. 262:250-260 
Weiler, E. W., T. M. Kutchan, T. Gorba, W. Brodschelm, U. 
Neisel, andF. Bublitz. 1994. ThePseudomonasphytotoxin 
coronatine mimics octadecanoid signaling molecules of 
higher plants. FEBS Lett. 345:9-13. 
The present invention will be further understood with ref-
erence to the following non-limiting experimental examples. 
EXAMPLES 
Example 1 
Genetically Improved Strains for Coronatine 
Production 
Use of the phytohormone coronatine (COR) as an abscis-
sion aid in the mechanical harvesting of citrus fruit has been 
described (see U.S. Pat. No. 6,511,939 to Bums et al., entitled 
"Coronatine as anAbscissionAgent for Citrus," the complete 
contents of which is incorporated herein by reference). How-
ever, a critical issue regarding the further development and 
utilization ofCOR is the low yield of the compound obtained 
by fermentation of COR-producing bacteria. Consequently, 
the aim of this invention was to improve the yields ofCOR 
through bacterial strain improvement. The approach used 
builds on existing knowledge of COR overproduction by 
strain Pseudomonas syringae DC3000-hrcC, a strain that 
contains a transposon insertion in hrcC, which encodes a 
component of the type III secretion system (Peiialoza-
Vazquez et al., 2000). Due to the unstable nature of the trans-
poson insertion in DC3000-hrcC, this strain was deemed 
unsuitable for commercial production ofCOR. Thus, the aim 
12 
tallography, and the absolute stereochemistry of CMA was 
established by X-ray analysis of its N-acetyl derivative (Ichi-
hara et al., 1977). Coronatine is generally the predominant 
coronafacoyl compound synthesized by Pseudomonas syrin-
5 gae. The coronafacic acid (CFA) portionofCOR shares struc-
tural and functional similarities to jasmonic acid (Feys et al., 
1994; Weiler et al., 1994) (FIG. 1), leading many researchers 
to assume that COR functions as a molecular mimic of jas-
monate. However, the coronamic acid (CMA) portion of 
10 COR is a structural analogue of aminocyclopropyl carboxylic 
acid (ACC), the immediate precursor of ethylene (Ferguson 
and Mitchell, 1985). The CMA portion ofCOR imparts addi-
tional biological activities to COR that are not induced by 
CFA alone (Palmer and Bender, 1995). In summary, the 
15 unique biological activities associated with COR suggest that 
it functions as a phytohormone, and this prompted investiga-
tions of the use of COR as an abscission aid for mechanical 
harvesting (Burns et al., 2003). Since a synthetic source of 
COR is not available, COR is currently obtained from the 
20 fermentation of the producing bacterium, Pseudomonas 
syringae. However, yields ofCOR from bacterial fermenta-
tions are low and remain a limiting factor in the utilization of 
COR as an abscission aid. In this Example, the development 
of an improved bacterial strain ( designated APVl) that pro-
25 duces significantly higher amounts of COR than the parent 
strain (DC3000) is described. 
Construction of the genetically modified strain, APVl. The 
goal of the experiments described herein was to generate a 
COR-overproducing strain of P. syringae by inserting a kana-
30 mycin resistance (Kmr) cassette into the hrcC gene of P. 
syringae DC3000 (FIG. 3). First, the hrcC gene was amplified 
from genomic DNA of P. syringae DC3000 using the poly-
merase chain reaction (PCR). The amplified hrcC gene was 
then cloned into the EcoRI restriction site present in pB!ue-
35 script SK+. The resulting construct was digested with Sphl, 
which cleaves hrcC once in the middle of the gene, but does 
not cut the vector, pBS. A Kmr cassette (Alexeyev, 1995) was 
ligated into the hrcC gene at the SphI site, resulting in a cloned 
copy ofhrcC: :Kmr. The construct containing hrcC: :Kmr was 
40 introduced into DC3000 and recombined into the genome 
using homologous recombination (Bender, et al. 1991). P. 
syringae DC3000 recombinants containing a Kmr-disrupted 
copy of hrcC (replacement of hrcC with hrcC::Km') were 
selected on media containing kanamycin and analyzed by 
45 Southern blotting and PCR (Keith and Bender, 1999; Yu et al., 
1999). The outcome was a COR-overproducing strain of P. 
syringae with a stable, selectable marker for maintaining the 
hrcC mutation ( e.g. kanamycin), and this derivative strain of the invention described below was to create a new, stable 
derivative ofDC3000 by inserting a genetic cassette encoding 
kanamycin resistance (Km') into the hrcC gene. Kanamycin 50 
is relatively inexpensive and has been used as a selectable 
marker in the construction of transgenic plants; consequently, 
this marker was chosen because it is predicted to be an accept-
able, economical method for selection of hrcC-mutated 
strains. The Kmr cassette is genetically stable (it does not 
contain genes for transposition), and the genetically 
improved strain that has been identified has several key char-
acteristics that make it attractive for production of COR. 
was designated APVl. 
P. syringae APVl produces high levels ofCOR at 26° C. A 
variety of nutritional and environmental factors have been 
previously examined to determine their effect on COR pro-
duction in the related strain, P. syringae pv. glycine a PG4180. 
Temperature had a highly significant effect on COR biosyn-
55 thesis and cor gene expression in PG4180, and 18° C. was an 
optimal temperature for both COR production and cor gene 
transcriptional activity (Palmer and Bender, 1993; Ullrich et 
al., 1995; Rohde et al., 1998) showed that COR production 
was thermoregulated in many strains of P. syringae pvs. atro-
Background Information 
Structure of coronatine. COR is an unusual molecule that 
can be hydrolyzed to yield two distinct components: (i) the 
polyketide coronafacic acid (CFA), and (ii) coronamic acid 
(CMA), an ethylcyclopropyl amino acid derived from isoleu-
cine (FIG. 1) (Ichihara et al., 1977). The structure and abso-
lute stereochemistry of CFA were elucidated by X-ray crys-
60 purpurea, maculicola, morsprunorum, and tomato, which 
may indicate that temperature is a common regulatory control 
for COR biosynthesis in other pathovars of P. syringae. The 
requirement of a low temperature for COR synthesis 
increases the cost of producing COR because the bacterial 
65 fermentation must be refrigerated. Thus we wanted to 
develop a strain of P. syringae that produced COR at condi-
tions more favorable for large scale fermentation. 
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COR production by the parent strain DC3000 and the 
genetically improved strain, APVl, was examined at 18, 26 
and 30° C. It was found that APVl produced approximately 
15 to 20-foldmoreCOR than the parent strain, DC3000 (FIG. 
4). Production of COR by the modified strain, APVl, was 5 
highest at 26° C., a temperature much more favorable for 
large-scale fermentation than 18° C. (the optimum for the 
parent strain, DC3000). In both strains, COR production was 
negligible when the fermentation was conducted at 30° C. In 
summary, APVl produces optimal levels of COR at 26° C., a 10 
temperature more appropriate for large scale fermentations. 
Another constraint to producing COR on a large-scale 
basis is the length of the fermentation period foroptimal CO R 
production. InP. syringae pv. glycinea PG4180, optimal COR 
production required a 7-day incubation period (Palmer and 15 
Bender, 1993 ). Thus we examined whether this would be true 
for the genetically improved strain, APVl. The results shown 
below (FIG. 5) indicate thatAPVl produces a large amount of 
COR when incubated for a 3-day period at 26° C. Therefore, 
the constraint of a long incubation period has been circum- 20 
vented in strain APVl. Further optimization of COR yields 
are disclosed in Example 2 below. 
The genes for pathogenicity are disabled in the genetically 
improved strain, APVl. In P. syringae pv. tomato DC3000, 
the type III secretion system (TTSS), which is encoded by the 25 
hrp/hrc gene cluster, is required for pathogenicity (Jin et al., 
2003) and the ability to grow within or on the surface of plants 
(Hirano et al., 1999). Therefore, disruptions in the hrp genes 
render P. syringae nonpathogenic and unable to fully colonize 
the surfaces of plant parts. The use of a nonpathogenic strain 30 
of P. syringae for the production of COR in bacterial fermen-
tations is desirable in terms of future use of the genetically 
improved strain for large-scale COR production. Thus, the 
genetically improved strain, APVl, was tested for its ability 
to colonize and cause disease on plants (Penaloza-Vazquez et 35 
al., 2000). StrainAPVl contains a mutation in the hrcC gene, 
which should render the strain both nonpathogenic and 
impaired for its ability to colonize plants. 
Tomato leaves were inoculated with P. syringae DC3000 
(parent strain) andAPVl (the genetically improved strain that 40 
overproduces COR) by spraying tomato leaves with inocu-
lum (106 cfu/ml) until leaf surfaces were uniformly wet. After 
inoculation, all plants were incubated in a growth chamber 
with a 12 h photoperiod at 24 ° C. and 90% relative humidity. 
Leaves sprayed with the parent strain DC3000 were severely 45 
diseased (FIG. 6a), whereas those inoculated with strain 
APVl were virtually symptom free (FIG. 6b). 
The ability of DC3000 (parent strain) and APVl (our 
modified strain) to colonize leaves of tomato, the host of P. 
syringae pv. tomato DC3000, was also monitored. Tomato 50 
leaves were sprayed with P. syringae pv. tomato DC3000 and 
APVl (106 cfu/ml) until surfaces were uniformly wet. After 
inoculation, all plants were incubated in a growth chamber 
with a 12 h photoperiod at 24 ° C. with 90% relative humidity. 
Leaves were sampled for the bacterial population using well- 55 
established methods (Penaloza-Vazquez et al., 2000). 
The results indicated that strainAPVl is severely impaired 
in its ability to persist and multiply in tomato leaves; for 
example, thepopulationofAPVl was 10,000-foldlowerthan 
the parent strain DC3000 at the end of the sampling period (9 60 
days) (FIG. 7). The impaired pathogenicity (FIG. 6B) and 
fitness (FIG. 7) of strain APVl bode well for the registration 
of this strain for COR production as it will not be classified as 
a pathogenic strain. 
In summary, there are several key advantages for using the 65 
genetically improved strain APVl for COR production: (1) 
significantly higher yields ofCOR are obtained withAPVl as 
14 
compared to the parent strain DC3000; (2) APVl produces 
optimal levels ofCOR at approximately 26° C., a temperature 
more appropriate for large-scale fermentations; (3) the lag 
time for optimal COR production by APVl was decreased 
(COR is produced earlier in the fermentation than observed 
for the parent strain); and (4) the modified strain APVl is 
nonpathogenic. 
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Example 2 
Optimization of Coronatine Production in a 
Genetically Improved Strain of Pseudomonas 
syringae 
16 
actively growing) have been successfully entrapped in vari-
ous matrices (Sharanagouda and Karegoudar, 2002; Tse and 
Yu, 2003; Wang et al., 2002; Yamamoto et al. 1980). As a 
result, reactions based on immobilized cell preparations offer 
5 several advantages compared to conventional fermentation 
including: (i) higher reaction rates due to increased cell den-
sities; (ii) higher specific product yield; (iii) continuous 
operation; (iv) reduced costs; and (v) ease of scale-up for 
commercial production (Banerjee et al., 2006; Diaz et al., 
10 2002; Wang et al., 2002). Table 1 provides examples where 
immobilized Pseudomonas spp. have been used to provide a 
commercially important compound or process. 
Coronatine (COR) is a phytohormone produced by several 15 
variants of Pseudomonas syringae (Bender et al., 1999). 
Coronatine shares significant structural and functional simi-
larities withjasmonic acid (FIG. 1), its precursor 12-oxophy-
todienoate, and methyl jasmonate, which are plant growth 
substances important in octadecanoid signaling (Weiler et al., 
1994). Components of the octadecanoid pathway regulate 
fruit ripening and abscission (Burns, 2002). This is germane 
20 
TABLE 1 
Production of various products or processes using 
different immobilization matrices and Pseudomonas spp. 
Pseudomonas 
Desired Product or Pro-
strains Matrix cess References 
GM3 Porous glass Biodegradation of Azo Tse and Yu, 
beads and solid Compounds 2003 to the present invention since COR has properties analogous 
to octadecanoid signaling molecules and has utility as a selec-
tive fruit loosening agent in citrus (Burns et al., 2003) (see 
also, U.S. Pat. No. 6,511,939 entitled "Coronatine as an 
AbscissionAgent for Citrus," the disclosure of which is incor-
porated herein by reference). Several factors have limited the 
ability to utilize COR as an abscission agent including: (i) the 
low yields obtained from the fermentation; (ii) a requirement 
of 18° C. for optimal production; and (iii) a long incubation 
period (7 days) for optimal levels of COR (Palmer and 
Bender, 1993; Burns et al., 2003 ). In this Example, conditions 
for optimizing the yield of COR in the fermentation of the 
genetically modified strain, APVl (see Example 1) are 
described. 
25 
30 
35 
ZD8 
TCP114 
NGK! 
M285 
P. dacunhae 
PVA particles 
Wood chips 
Calcium 
alginate 
Calcium 
alginate 
Diatomaceous 
earth beads 
Carrageenan 
Filtration of air Miao etal., 
pollutants (Biodegra- 2005 
dation of rapeseed 
oil smoke) 
Degradation of Bae et al., 1997 
2,4,6-trichlorophenol 
Degradation of Sharanagouda 
2-methylnaphthalene & Karegoudar, 
2002 
Degradation of Feng et al, 
3 ,5 ,6-trichloro- 1997 
2-pyridinol from 
industrial wastewater 
Production of Yamamoto 
L-alanine et al., 1980 
The support matrix for immobilization must have an adapt-
able pore capacity and diameter to avoid loss of cells and 
provide optimal conditions for transport of substrates and the 
elimination of metabolites (Zahar-Perez et al., 2003; Wang et 
al. 2002). Consequently, there is no universal optimal support 
system because requirements for particular applications dif-
fer (Brodelius and Mosbach, 1987). The choice of the proper 
This Example 2 describes conditions for optimal produc-
tion of COR by the genetically improved strain, APVl. P. 
syringae strainAPVl produces substantially higher levels of 
COR than the parent strain, DC3000, and production ofCOR 40 
by APVl is optimal at 26° C., a temperature more favorable 
for large-scale fermentation than 18° C., which is the optimal 
temperature for DC3000. This and other aspects of the inven-
tion are elaborated in one or more of the embodiments 
described below. 45 carrier or support is governed by factors such as cost, ease of 
preparation, mechanical stability, biocompatibility, and resis-
tance to biodegradation (Brodelius and Mosbach, 1987). 
One embodiment of the invention presents the results of 
using immobilized cells of Pseudomonas to produce COR. 
Immobilization of bacterial cells on a matrix facilitates mem-
brane stabilization, which protects cells and improves viabil-
ity. In these experiments, the yield of COR is compared for 
freely suspended cells of APVl and cells of APVl entrapped 
in various matrices. Another embodiment of the invention 
provides a method to immobilize Pseudomonas cells in two 
different matrices: (1) calcium alginate and (2) Cytoline™ 2; 
the latter is a novel microcarrier consisting of polyethylene 
and silica (Amersham Biosciences). The invention describes 
the use of immobilized cells of APVl to produce COR at 26° 
C. within a 24 h incubation period. The end result is a method 
to produce COR in a cost-effective manner. 
Use of immobilized cells of Pseudomonas to produce 
COR. The literature on the use of immobilized cells for the 
production of secondary metabolites is considerable (Baner-
jee et al., 2006; Shan et al., 2003; Tse and Yu, 2003). Immo-
bilization of bacterial cells on a matrix is known to facilitate 
membrane stabilization, which protects cells and improves 
viability (Hann et al. 2002; Sharanagouda and Karegoudar, 
2002). Cells at different stages (dead, resting/living, and 
Experimental approach. Two methods of cell immobiliza-
50 tion were screened. Cells of P. syringae strain APVl (the 
genetically improved strain) were entrapped in two different 
support matrices, and the amounts of COR produced were 
compared with the levels produced by freely suspended cells 
in batch fermentation. For both immobilized and free cells, 
55 the initial cell density was OD600=1.37, and COR production 
was calculated as the volumetric rate of production (COR 
g/L/h) after each cycle of COR production (e.g. 24 h). The 
two support matrices tested were calcium alginate and Cyto-
line™ 2, which is a microcarrier consisting of polyethylene 
60 and silica (Amersham Biosciences). Calcium alginate was 
prepared as described previously (Bucke, 1987; see FIG. 8), 
and Cytoline 2 was prepared as described by the manufacturer 
(Amersham). COR production was evaluated in repeated 
batch fermentations for free and immobilized cells of strain 
65 APVl. After removing the exhausted medium, the cells were 
washed with sterile water, and 30 ml of fresh culture medium 
was added for the next cycle of fermentation (1 cycle=24 h). 
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Hann, E. C.,A. E. Sigmund, S. M. Hennessey, J.E. Gavagan, 
D.R. Short,A. Ben-Bassat, S. Chauhan, R. D. Fallon, M. S. 
Payne, andR. DiCosimo. (2002) Optimizationofanimmo-
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(1977) The structure of coronatine. J. Am. Chem. Soc. 99: 
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Result. After the fifth cycle, COR production was 559, 200, 
and 12 µg/ml for Cytoline™ 2-immobilized cells, calcium 
alginate-immobilized cells, and free cells of APVl, respec-
tively (FIG. 9). These results indicate that COR yields are 
substantially higher when immobilized cells of P. syringae 5 
are used. Furthermore, Cytoline™ 2 was superior to calcium 
alginate as an immobilization matrix and did not show any 
decomposition during repeated cycles of fermentation. 
Decomposition was a problem observed with calcium algi-
nate, possibly because P. syringae produces alginate lyase, an 
enzyme that degrades alginate. 
In summary, a procedure foroptimal production of CO R by 
the genetically improved strain APVl has been identified. 
Using Cytoline™ 2 as an immobilization matrix, COR pro-
duction by APVl was increased to 400 µg/ml at 24 h. This is 15 
approximately 100-fold higher than the amount of COR syn-
thesized by free cells of APVl (FIG. 9). The use of immobi-
lized cells and the implementation of strainAPVl have made 
10 Miao, J. Y., Zheng, L. Y., and Guo, X. F. (2005) Restaurant 
emissions removal by a biofilter with immobilized bacte-
ria. J. Zhejiang Univ. Sci. B 6: 433-437. 
it possible to produce large amounts of COR with minimal lag 
time, thus increasing opportunities to bring the compound to 20 
market as an abscission aid. 
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In view of the above, it will be seen that the several objec-
tives of the invention are achieved and other advantageous 
results attained. As various changes could be made without 
departing from the scope of the invention, it is intended that 
all matter contained in the above description or shown in the 
accompanying drawings shall be interpreted as illustrative 
and not in a limiting sense. 
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<220> FEATURE, 
<223> OTHER INFORMATION: sequence from synthetic plasmid encoding kanamycin resistance 
<400> SEQUENCE, 1 
atgattgaac aagatggatt gcacgcaggt tctccggccg cttgggtgga gaggctattc 60 
ggctatgact gggcacaaca gacaatcggc tgctctgatg ccgccgtgtt ccggctgtca 120 
gcgcaggggc gcccggttct ttttgtcaag accgacctgt ccggtgccct gaatgaactc 180 
caagacgagg cagcgcggct atcgtggctg gccacgacgg gcgttccttg cgcagctgtg 240 
ctcgacgttg tcactgaagc gggaagggac tggctgctat tgggcgaagt gccggggcag 300 
gatctcctgt catctcacct tgctcctgcc gagaaagtat ccatcatggc tgatgcaatg 360 
cggcggctgc atacgcttga tccggctacc tgcccattcg accaccaagc gaaacatcgc 420 
atcgagcgag cacgtactcg gatggaagcc ggtcttgtcg atcaggatga tctggacgaa 480 
gagcatcagg ggctcgcgcc agccgaactg ttcgccaggc tcaaggcgcg gatgcccgac 540 
ggcgaggatc tcgtcgtgac ccatggcgat gcctgcttgc cgaatatcat ggtggaaaat 600 
ggccgctttt ctggattcat cgactgtggc cggctgggtg tggcggaccg ctatcaggac 660 
atagcgttgg ctacccgtga tattgctgaa gagcttggcg gcgaatgggc tgaccgcttc 720 
ctcgtgcttt acggtatcgc cgctcccgat tcgcagcgca tcgccttcta tcgccttctt 780 
gacgagttct tctga 795 
<210> SEQ ID NO 2 
<211> LENGTH, 1941 
<212> TYPE, DNA 
<213> ORGANISM: Pseudomonas syringae 
<400> SEQUENCE, 2 
atgtcgctcg acatgtcgcc tgtccagggc aagctcgatg gccgtattcg tgctcagaac 
cctgaagagt ttcttgagcg gctgagtcag gaataccact tccagtggtt cgtctataac 
gacacgctgt atgtcagccc ttccagcgag cacacctcgg cgcgcatcga agtctcgccg 
gatgcggtgg acgacctgca aacggcgctg accgatgtcg gtctgctgga caagcgtttt 
ggctggggct cgctgcctga cgaaggcgtg gttctggttc gtggtccggc caaatacgtg 
gagtttgtgc gcgactacag caagaaagtc gaaaagcccg acgagaaggc cgacaagcaa 
gatgttgtcg tgctgccact caaatacgcc aacgcggctg atcggactat tcgctaccgt 
gaccagcagt tagtggtggc cggtgtcgcc agtattcttc aagagctgct ggaaagccgt 
tcgcgtggcg aaagcattga cagcgtgaac ctgttgccgg ggcagggcag cagtgttgcc 
aacagcacag gtgtcgcggc cgccggcctg ccttacaacc tgggctccaa tggtatcgat 
acgggagcac tgcaacaggg cattgaccgc gtattgaact tcaacagcaa aaaaactgcc 
aagggtcatg cctcaggcaa ggcaaatatc cgcgtaagcg ctgatgtgcg taacaactcc 
gtattgattt acgacctgcc agagcgcaag gccatgtacc agaaactggt caaggagctg 
gacgttccgc gcaacctgat cgaaatcgat gcggtcattc tcgacatcga ccgcaatgaa 
ctggctgaac tgtccagtcg ctggaatttc aatgccggca gcgtcggagg tggtgccaac 
ctgtttgatg caggcaccag ttcaacgttg ttcttgcaga acgccagcaa gttttctgcc 
gaattgcatg cgcttgaagg caatggttct gcgtcagtca tcggcaaccc gtcgatcctg 
accctggaga atcagcctgc agtgatcgac ctcagtcgca ccgaatacct gacggccact 
tccgagcggg ccgctgacat tctgcccatc acggcgggca ccagccttca agtgattccg 
60 
120 
180 
240 
300 
360 
420 
480 
540 
600 
660 
720 
780 
840 
900 
960 
1020 
1080 
1140 
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cgttcgctgg acaacgatgg caagcctcag gtgcaaatga tcgtggacat cgaggatggc 1200 
cagatcgatg tgtcgacgat caatgacacc caacccagtg tgcgccgagg caatgtcagc 1260 
acccaggcgg tgattgccga gcacggctcg ctggtcatcg gcggcttcca cggtctggaa 1320 
gccaatgaca ggattcacaa gatcccgctg ttgggcgaca ttccctatat cggcaagctg 1380 
ctgttccagt cccgcagtcg cgaactgagt cagcgcgagc ggctgttcat tctgacccct 1440 
cgactgatcg gcgatcaggt caatccagca cgctatgtac agaacggcaa cccccatgac 1500 
gtcgatgacc agatgaagaa aatcaaggaa cgacgtgacg gaggcgagct gccaacgcgg 1560 
ggcgacatcc agaaagtctt tacccaaatg atcgacggcg ccgccccgga aggcctgcgc 1620 
gctggccaga ccctgccctt tgaaaccgat agtctgtgtg atccgggcga aggtctgacg 1680 
cttgatgggc agcgctcgca gtggttcgtc aaaaaagact ggggtgttgc tgtggtggtt 1740 
gcgcgtaaca acacggacaa gccggtacgt atcgacgaaa gccgatgcgg cggtcgctgg 1800 
gtcatcggcg ttgcggcctg gcctcatgca tggctgcagc cgggtgaaga aagtgaggtg 1860 
tacatcgctg tgcgccagcc gcagatatct aaaatggcca aagaaagcag gccgtcactg 1920 
ctccggggag cgaaaccatg a 1941 
<210> SEQ ID NO 3 
<211> LENGTH, 3126 
<212> TYPE, DNA 
<213> ORGANISM, Artificial 
<220> FEATURE, 
<223> OTHER INFORMATION, P. syringae hrcC gene disrupted by kanamycin resistance gene at 
SphI site 
<400> SEQUENCE, 3 
atgtcgctcg acatgtcgcc tgtccagggc aagctcgatg gccgtattcg tgctcagaac 60 
cctgaagagt ttcttgagcg gctgagtcag gaataccact tccagtggtt cgtctataac 120 
gacacgctgt atgtcagccc ttccagcgag cacacctcgg cgcgcatcga agtctcgccg 180 
gatgcggtgg acgacctgca aacggcgctg accgatgtcg gtctgctgga caagcgtttt 240 
ggctggggct cgctgcctga cgaaggcgtg gttctggttc gtggtccggc caaatacgtg 300 
gagtttgtgc gcgactacag caagaaagtc gaaaagcccg acgagaaggc cgacaagcaa 360 
gatgttgtcg tgctgccact caaatacgcc aacgcggctg atcggactat tcgctaccgt 420 
gaccagcagt tagtggtggc cggtgtcgcc agtattcttc aagagctgct ggaaagccgt 480 
tcgcgtggcg aaagcattga cagcgtgaac ctgttgccgg ggcagggcag cagtgttgcc 540 
aacagcacag gtgtcgcggc cgccggcctg ccttacaacc tgggctccaa tggtatcgat 600 
acgggagcac tgcaacaggg cattgaccgc gtattgaact tcaacagcaa aaaaactgcc 660 
aagggtcatg cctcaggcaa ggcaaatatc cgcgtaagcg ctgatgtgcg taacaactcc 720 
gtattgattt acgacctgcc agagcgcaag gccatgtacc agaaactggt caaggagctg 780 
gacgttccgc gcaacctgat cgaaatcgat gcggtcattc tcgacatcga ccgcaatgaa 840 
ctggctgaac tgtccagtcg ctggaatttc aatgccggca gcgtcggagg tggtgccaac 900 
ctgtttgatg caggcaccag ttcaacgttg ttcttgcaga acgccagcaa gttttctgcc 960 
gaattgcatg cctgcagtcg actctagagg atcccgggta ccgagctcga attcgctagc 1020 
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ttcacgctgc cgcaagcact cagggcgcaa gggctgctaa aggaagcgga acacgtagaa 1080 
agccagtccg cagaaacggt gctgaccccg gatgaatgtc agctactggg ctatctggac 1140 
aagggaaaac gcaagcgcaa agagaaagca ggtagcttgc agtgggctta catggcgata 1200 
gctagactgg gcggttttat ggacagcaag cgaaccggaa ttgccagctg gggcgccctc 1260 
tggtaaggtt gggaagccct gcaaagtaaa ctggatggct ttcttgccgc caaggatctg 1320 
atggcgcagg ggatcaagat ctgatcaaga gacaggatga ggatcgtttc gcatgattga 1380 
acaagatgga ttgcacgcag gttctccggc cgcttgggtg gagaggctat tcggctatga 1440 
ctgggcacaa cagacaatcg gctgctctga tgccgccgtg ttccggctgt cagcgcaggg 1500 
gcgcccggtt ctttttgtca agaccgacct gtccggtgcc ctgaatgaac tccaagacga 1560 
ggcagcgcgg ctatcgtggc tggccacgac gggcgttcct tgcgcagctg tgctcgacgt 1620 
tgtcactgaa gcgggaaggg actggctgct attgggcgaa gtgccggggc aggatctcct 1680 
gtcatctcac cttgctcctg ccgagaaagt atccatcatg gctgatgcaa tgcggcggct 1740 
gcatacgctt gatccggcta cctgcccatt cgaccaccaa gcgaaacatc gcatcgagcg 1800 
agcacgtact cggatggaag ccggtcttgt cgatcaggat gatctggacg aagagcatca 1860 
ggggctcgcg ccagccgaac tgttcgccag gctcaaggcg cggatgcccg acggcgagga 1920 
tctcgtcgtg acccatggcg atgcctgctt gccgaatatc atggtggaaa atggccgctt 1980 
ttctggattc atcgactgtg gccggctggg tgtggcggac cgctatcagg acatagcgtt 2040 
ggctacccgt gatattgctg aagagcttgg cggcgaatgg gctgaccgct tcctcgtgct 2100 
ttacggtatc gccgctcccg attcgcagcg catcgccttc tatcgccttc ttgacgagtt 2160 
cttctgagcg ggactctggg gttcgaattc gagctcggta cccggggatc cgtcgactgc 2220 
agcatgcgct tgaaggcaat ggttctgcgt cagtcatcgg caacccgtcg atcctgaccc 2280 
tggagaatca gcctgcagtg atcgacctca gtcgcaccga atacctgacg gccacttccg 2340 
agcgggccgc tgacattctg cccatcacgg cgggcaccag ccttcaagtg attccgcgtt 2400 
cgctggacaa cgatggcaag cctcaggtgc aaatgatcgt ggacatcgag gatggccaga 2460 
tcgatgtgtc gacgatcaat gacacccaac ccagtgtgcg ccgaggcaat gtcagcaccc 2520 
aggcggtgat tgccgagcac ggctcgctgg tcatcggcgg cttccacggt ctggaagcca 2580 
atgacaggat tcacaagatc ccgctgttgg gcgacattcc ctatatcggc aagctgctgt 2640 
tccagtcccg cagtcgcgaa ctgagtcagc gcgagcggct gttcattctg acccctcgac 2700 
tgatcggcga tcaggtcaat ccagcacgct atgtacagaa cggcaacccc catgacgtcg 2760 
atgaccagat gaagaaaatc aaggaacgac gtgacggagg cgagctgcca acgcggggcg 2820 
acatccagaa agtctttacc caaatgatcg acggcgccgc cccggaaggc ctgcgcgctg 2880 
gccagaccct gccctttgaa accgatagtc tgtgtgatcc gggcgaaggt ctgacgcttg 2940 
atgggcagcg ctcgcagtgg ttcgtcaaaa aagactgggg tgttgctgtg gtggttgcgc 3000 
gtaacaacac ggacaagccg gtacgtatcg acgaaagccg atgcggcggt cgctgggtca 3060 
tcggcgttgc ggcctggcct catgcatggc tgcagccggg tgaagaaagt gaggtgtaca 3120 
tcgctg 3126 
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We claim: 
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wherein said bacterial strain is a Gram negative strain, and 
wherein said stable bacterial strain contains a genetically 
engineered mutation of a type III secretion system gene 
resulting from insertion of a cassette that does not contain 
1. A stable genetically engineered bacterial strain that over-
produces coronatine, wherein said bacterial strain is a Gram 
negative strain, and wherein said stable bacterial strain con-
tains a genetically engineered mutation of a type III secretion 
system gene resulting from insertion of a cassette that does 
not contain genes for transposition. 
5 genes for transposition, 
2. The stable genetically engineered bacterial strain of 
claim 1, wherein said stable bacterial strain is aPseudornonas 
syringae bacterial strain. 
and removing coronatine produced by said stable geneti-
cally engineered bacterial strain in said culture medium. 
13. The method of claim 12, wherein said stable genetically 
engineered bacterial strain is immobilized on a matrix in said 
10 culture medium. 
3. The stable genetically engineered bacterial strain of 
claim 1, wherein said genetically engineered mutation is an 
insertion of a stable genetic element. 
4. The stable genetically engineered bacterial strain of 
claim 3, wherein said stable genetic element is an antibiotic 15 
resistance cassette. 
14. The method of claim 13, wherein said stable genetically 
engineered bacterial strain is immobilized on Cytoline™ as a 
matrix. 
15. The method of claim 12, wherein said stable genetically 
engineered bacterial strain is a Pseudomonas syringae bacte-
rial strain. 
5. The stable genetically engineered bacterial strain of 
claim 4, wherein the antibiotic resistance cassette is from the 
aminoglycoside phosphotransferase class of antibiotic resis-
tance genes. 
16. The method of claim 12, wherein said genetically engi-
neered mutation is an insertion of a stable genetic element. 
17. The method of claim 16, wherein said stable genetic 
20 element is an antibiotic resistance cassette. 
6. The stable genetically engineered bacterial strain of 
claim 4, wherein said antibiotic resistance cassette is a kana-
mycin resistance (Kmr) cassette. 
7. The stable genetically engineered bacterial strain of 
claim 1, wherein said type III secretion system gene is hrcC. 25 
8. The stable genetically engineered bacterial strain of 
claim 7, wherein said stable genetic element is inserted into 
an Sphl cleavage site within the hrcC gene. 
9. The stable genetically engineered bacterial strain of 
claim 1, wherein said stable genetically engineered bacterial 30 
strain is non-pathogenic. 
10. The stable genetically engineered bacterial strain of 
claim 1, wherein said stable genetically engineered bacterial 
strain produces optimal levels of coronatine at 26° C. 
11. A stable genetically engineered bacterial strain that 35 
overproduces coronatine, wherein said stable genetically 
engineered bacterial strain is a Pseudomonas syringae bacte-
rial strain, and wherein said stable bacterial strain contains a 
genetically engineered mutation of a type III secretion system 
gene resulting from insertion of a cassette that does not con- 40 
tain genes for transposition. 
12. A method of producing coronatine, comprising the 
steps of culturing in a culture medium a stable genetically 
engineered bacterial strain that overproduces coronatine, 
18. The method of claim 17, wherein said antibiotic resis-
tance cassette is a kanamycin resistance (Km-) cassette. 
19. The method of claim 12, wherein said type III secretion 
system gene is hrcC. 
20. The method of claim 19, wherein said stable genetic 
element is inserted into an Sphl cleavage site within the hrcC 
gene. 
21. The method of claim 12, wherein said stable genetically 
engineered bacterial strain is non-pathogenic. 
22. The method of claim 12, wherein said step of culturing 
is carried out at 20° C. to 30° C. 
23. The method of claim 12, wherein said stable genetically 
engineered bacterial strain produces optimal levels of coro-
natine at 26° C. 
24. A matrix comprising a stable genetically engineered 
Gram negative bacterial strain that overproduces coronatine 
immobilized thereon, wherein said stable bacterial strain con-
tains a genetically engineered mutation of a type III secretion 
system gene resulting from insertion of a cassette that does 
not contain genes for transposition. 
25. The matrix of claim 24, wherein said matrix comprises 
polyethylene weighted with silica. 
* * * * * 
